ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,192.38
0.22%
US Tech 100
17,669.20
0.34%
다우존스 지수
38,891.43
0.10%
Bitcoin
63,570.48
0.64%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NYSE
  6. Takeda Pharmaceutical Company Ltd (TAK)

  7. Takeda Pharmaceutical Company Ltd (TAK) 뉴스

TAK Takeda Pharmaceutical Company Ltd

13.28
-0.08 (-0.60%)
최종 업데이트: 01:41:30
15분 지연
기업명 주식 심볼 시장 주식 타입
Takeda Pharmaceutical Company Ltd TAK NYSE 주식예탁증서 (DR)
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
-0.08 -0.60% 13.28 01:41:30
개장가 저가 고가 종가 전일 종가
13.27 13.22 13.29 13.36
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
26/04/202421:30BWTakeda Receives Positive CHMP Opinion for Fruquintinib in..
23/04/202420:00PRNUSNeurocrine Biosciences Reports Positive Phase 2 Data for..
22/04/202417:10PRNUSTakeda, Astellas and Sumitomo Mitsui Banking Announce Master..
19/04/202408:00BWU.S. FDA Approves Subcutaneous Administration of Takeda’s..
08/04/202421:00BWTakeda Announces New U.S. Corporate Social Responsibility..
27/03/202421:56PRNUSEmpathy in Action: Takeda's Global Initiative Brings IBD..
27/03/202421:53PRNUSEmpathy in Action: Takeda's Global Initiative Brings IBD..
27/03/202414:01BWTakeda gibt Kandidaten für den Vorstand bei der kommenden..
27/03/202408:07BW武田薬品工業: 第148回定時株主総会に提案する取締役候補者について
26/03/202421:00BWTakeda Announces Approval of ADZYNMA® Intravenous Injection..
21/03/202422:39BW武田薬品、Ph+..
21/03/202416:33BWTakeda meldet sNDA-Zulassung von ICLUSIG® (Ponatinib) durch..
21/03/202404:18BWTakeda annonce l'approbation par la FDA des États-Unis d'une..
20/03/202401:20BWTakeda Announces U.S. FDA Approval of Supplemental New Drug..
19/03/202419:30GLOBECENTOGENE Extends Strategic Partnership With Takeda to..
13/03/202421:00BWTakeda Announces Positive Topline Results from Phase 2 Study..
28/02/202421:03BW武田薬品とBiological E. Limited、デング熱流行地域におけるワクチンへのアクセス促進で協力
28/02/202407:26BWTakeda et Biological E. Limited s’associent pour accélérer..
27/02/202421:38BWTakeda und Biological E. Limited arbeiten zusammen, um den..
27/02/202413:30BWTakeda and Biological E. Limited Collaborate to Accelerate..
26/02/202421:00PRNCAChampioning Rare Voices on Rare Disease Day
12/02/202422:00BWFDA Approves Takeda’s EOHILIA (budesonide oral suspension),..
09/02/202408:00BWTakeda Intends to Rapidly Initiate the First Global Phase 3..
02/02/202406:23BWTakeda gibt Nachfolger für die Position des Chief Financial..
02/02/202406:18BWTakeda annonce la succession de son directeur financier
01/02/202423:59BWTakeda gibt Ergebnisse für das dritte Quartal des..
01/02/202420:18EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/02/202420:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/02/202415:54BWTakeda Announces Chief Financial Officer Succession
01/02/202415:02BWTakeda Announces Third-Quarter FY2023 Results; On-Track..
31/01/202401:00BW武田薬品、慢性炎症性脱髄性多発根神経炎（CIDP）に対する維持療法としてのHYQVIA®について、欧州委員会から承認を獲得
30/01/202422:04BWTakeda-Arzneimittel HYQVIA ® von der Europäischen Kommission..
30/01/202403:55BWLe HYQVIA® de Takeda approuvé par la Commission européenne..
30/01/202401:10BWTakeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults..
29/01/202416:00BWTakeda’s HYQVIA® Approved by European Commission as..
26/01/202407:00PRNUSCognizant Helping to Modernize Infrastructure and..
25/01/202420:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/01/202420:11EDGAR2Form SC 13D/A - General statement of acquisition of..
19/01/202420:03EDGAR2Form SC 13G - Statement of acquisition of beneficial..
19/01/202403:56BWTakeda est nommée Top Employer mondial pour la septième..
19/01/202403:45BW武田薬品工業、7年連続でトップ・エンプロイヤーに認定
19/01/202403:22BWTakeda im siebten Jahr in Folge international als Top..
18/01/202421:00BWTakeda Named Global Top Employer for Seventh Consecutive..
16/01/202422:00BWU.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in..
16/01/202420:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/12/202306:00BWTakeda Announces China NMPA Approval of LIVTENCITY®..
20/12/202321:01PRNCATakeda Enters Into Two-Year Contract with Canadian Blood..
17/12/202301:36BWTakeda obtient l’avis favorable du CHMP pour HYQVIA® en tant..
17/12/202300:47BWTakeda erhält positive CHMP-Stellungnahme für HYQVIA® als..
15/12/202322:16BWTakeda Receives Positive CHMP Opinion for HYQVIA® as..

최근 히스토리

NYSE
TAK
Takeda Pharmaceutical
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유